Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RABGGTB | P53611 | 9/20 | 0.66 |
| ▸ | RABGGTA | Q92696 | 9/20 | 0.66 |
| ▸ | CRHBP | P24387 | 2/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CCR6 | P51684 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10047262 | 1.00 | RABGGTB (0.66) | RABGGTBRABGGTACRHBPCRHR2TAS2R14 | |
| SCHEMBL10047264 | 0.90 | RABGGTB (0.81) | RABGGTBRABGGTACRHBPCRHR2 | |
| SCHEMBL10073606 | 0.90 | RABGGTB (0.81) | RABGGTBRABGGTACRHBPCRHR2 | |
| SCHEMBL10072993 | 0.86 | RABGGTB (0.77) | RABGGTBRABGGTACRHBPCRHR2 | |
| SCHEMBL14882690 | 0.86 | RABGGTB (0.77) | RABGGTBRABGGTACRHBPCRHR2 | |
| SCHEMBL10047249 | 0.86 | RABGGTB (0.77) | RABGGTBRABGGTACRHBPCRHR2 | |
| SCHEMBL10073972 | 0.85 | RABGGTB (0.62) | RABGGTBRABGGTACRHBPCRHR2TAS2R14 | |
| SCHEMBL10047281 | 0.85 | RABGGTB (0.62) | RABGGTBRABGGTACRHBPCRHR2TAS2R14 | |
| SCHEMBL10073815 | 0.85 | RABGGTB (0.62) | RABGGTBRABGGTACRHBPCRHR2 | |
| SCHEMBL10047267 | 0.85 | RABGGTB (0.62) | RABGGTBRABGGTACRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093274-B2 | Inhibitors of protein prenyltransferases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100063114-A1 | INHIBITORS OF PROTEIN PRENYLTRANSFERASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063114-A1 | INHIBITORS OF PROTEIN PRENYLTRANSFERASES | GGT1, FNTA, FNTB | RABGGTB 17/4885RABGGTA 5/4885CRHBP 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.